Abiopharma

🔍 Bradway Robert A (Director)

Company: AMGEN INC (AMGN)

Report Date: 2026-05-02

Detailed Transactions and Holdings:

• Sold 2,631 shares of Common Stock at $329.82 per share (Direct)
  Date: 2026-05-02 | Code: F | equity_swap_involved: 0 | shares_owned_after: 499,231.00 | transaction_form_type: 4
• Sold 2,426 shares of Common Stock at $329.82 per share (Direct)
  Date: 2026-05-02 | Code: F | equity_swap_involved: 0 | shares_owned_after: 496,805.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-02 | Code: H | nature_of_ownership: By GRAT | shares_owned_after: 60,060.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-02 | Code: H | nature_of_ownership: By Spousal GRAT | shares_owned_after: 60,060.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-02 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 29,940.00

Footnotes:

• F1: These shares include 1,624 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.